Advancements in X-Linked Retinitis Pigmentosa Research

For the inherited retinal disease (IRD) community, clinical trial updates represent vital milestones in the journey toward effective treatments. According to a report by Ophthalmology Times Europe, a novel gene therapy known as AGTC-501, developed by Applied Genetic Technologies Corporation, has demonstrated an acceptable safety profile and visual function improvements at higher doses in early-stage clinical evaluations.

Key Findings from the Phase 1/2 Study

X-linked retinitis pigmentosa (XLRP) is an inherited retinal disease beginning in childhood that causes night blindness, progressive loss of peripheral vision, and eventual central vision loss. It is frequently caused by mutations in the RPGR gene, which accounts for roughly 10% of retinitis pigmentosa cases.

According to Dr. Robert A. Sisk, director of pediatric vitreoretinal surgery and director of ophthalmic genetics at Cincinnati Children's Hospital and the Cincinnati Eye Institute, safety and efficacy findings from a 12-month Phase 1/2 study of AGTC-501—a recombinant adeno-associated virus (AAV) 2 vector—revealed encouraging outcomes. The trial included 29 male patients aged 6 years and older with the RPGR mutation who received a single sub-retinal injection.

Key data points reported from the trial include:
- No serious adverse safety issues were highlighted in the primary safety assessments.
- Among 20 patients who received central retinal injections, mean visual acuity improved by approximately five letters compared to untreated fellow eyes.
- Microperimetry sensitivity showed improvements at Month 12 across centrally dosed patients.
- Optical coherence tomography (OCT) revealed encouraging anatomical correlates of ellipsoid zone (EZ) improvement.

What This Means for Patients and Families

Currently, therapeutic options for individuals living with inherited retinal diseases remain exceedingly limited, with only one FDA-approved gene therapy available for a specific subset of retinal disease. Progress in addressing mutations like RPGR brings cautious optimism to patients and families affected by the severe, early-onset degeneration characteristic of XLRP.

Looking Ahead

Clinical trials evaluating AGTC-501 are continuing through broader research initiatives, including the Skyline trial expansion and the Vista Phase 2/3 safety and efficacy clinical trial. The IRD community will continue to monitor these developments as researchers gather further data on safety and long-term visual outcomes.